Clinical Trial Update: Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating selinexor in combination with R-GemOx as second-line therapy for diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• R-GemOx (rituximab, gemcitabine, oxaliplatin)
• Selinexor (selinexor)

Snippet

Sponsor: Chongqing University Cancer Hospital | Conditions: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 4 | Status: UNKNOWN